Marinus Pharma (MRNS) Reports In-Line Q4 EPS

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.77), in-line with the analyst estimate of ($0.77). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $3.46 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BTIG Starts Take-Two Interactive (TTWO) at Buy
• Worthington Industries (WOR) Misses Q4 EPS by 9c